8,700 Studies Reviewed. 87.0% Found Biological Effects. The Evidence is Clear.

Effect of 2400 MHz mobile phone radiation exposure on the behavior and hippocampus morphology in Swiss mouse model

Bioeffects Seen

Hasan I, Jahan MR, Islam MN, Islam MR · 2022

Share:

The study concludes that 2400 MHz RF-EMR exposure affects hippocampal structural integrity in mice, correlating with behavioral changes such as increased anxiety.

Plain English Summary

Summary written for general audiences

This study examined the effects of 2400 MHz radiofrequency electromagnetic radiation (4G mobile phone radiation) on behavior and hippocampal structure in Swiss albino mice exposed for 40 or 60 minutes daily over 60 days. The researchers found that exposed mice showed increased anxiety-like behavior, neuronal degeneration in the hippocampus, and significant decreases in pyramidal and granule neuron counts compared to control mice.

Why This Matters

This is an animal model study using established behavioral testing (elevated plus-maze) and histological/stereological methods to quantify neuronal changes. The findings are consistent with some prior research suggesting RF-EMR effects on the nervous system, though results from animal models do not necessarily translate directly to human health outcomes.

Exposure Information

Specific exposure levels were not quantified in this study.

Cite This Study
Hasan I, Jahan MR, Islam MN, Islam MR (2022). Effect of 2400 MHz mobile phone radiation exposure on the behavior and hippocampus morphology in Swiss mouse model.
Show BibTeX
@article{hasan_i_jahan_mr_islam_mn_islam_mr_ce3262,
  author = {Hasan I and Jahan MR and Islam MN and Islam MR},
  title = {Effect of 2400 MHz mobile phone radiation exposure on the behavior and hippocampus morphology in Swiss mouse model},
  year = {2022},
  doi = {10.1016/S0140-6736(22)00163-5},
  
}

Quick Questions About This Study

This appears to be a database categorization error. The study examined monoclonal antibody treatments for COVID-19 patients and contains no electromagnetic field research or data whatsoever.
The study tested casirivimab and imdevimab antibody treatments in 9,785 hospitalized COVID-19 patients across 127 UK hospitals, measuring 28-day mortality rates compared to standard care.
Yes, but only in patients without existing COVID antibodies. The treatment reduced death rates by 21% in seronegative patients but showed no benefit in those with prior antibodies.
The RECOVERY trial enrolled 9,785 eligible patients, with 4,839 receiving the antibody treatment plus usual care and 4,946 receiving usual care alone between September 2020 and May 2021.
No significant safety issues were found. There were no treatment-related deaths and only seven patients (<1%) experienced serious adverse reactions believed related to the antibody combination treatment.